|
21 Nov 2019 |
Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology
|
|
21 Nov 2019 |
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
|
|
21 Nov 2019 |
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
|
|
21 Nov 2019 |
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
|
|
20 Nov 2019 |
Hope Biosciences Receives FDA Approval to Commence Groundbreaking Stem Cell Clinical Trial for Alzheimer’s Disease
|
|
19 Nov 2019 |
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
|
|
19 Nov 2019 |
Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation
|
|
19 Nov 2019 |
Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program
|
|
19 Nov 2019 |
Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting
|
|
19 Nov 2019 |
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck Cancer
|
|
19 Nov 2019 |
Codiak Presents First Preclinical Data for exoASO, Engineered Exosomes Designed to Reprogram Tumor-Associated Macrophages
|
|
18 Nov 2019 |
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
|
|
18 Nov 2019 |
The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
|
|
16 Nov 2019 |
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
|
|
16 Nov 2019 |
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
|
|
16 Nov 2019 |
Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program
|
|
13 Nov 2019 |
Kiadis Pharma changes strategy to focus solely on development of Natural Killer (NK) Cell therapeutics and terminates development of ATIR101
|
|
12 Nov 2019 |
Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
|
|
12 Nov 2019 |
Solid Biosciences Provides SGT-001 Program Update
|
|
12 Nov 2019 |
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program
|
|
12 Nov 2019 |
BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis
|
|
11 Nov 2019 |
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem™ in Acute-on-Chronic Liver Failure
|
|
10 Nov 2019 |
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
|
|
10 Nov 2019 |
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
|
|
08 Nov 2019 |
Torque Presents New Preclinical Data for Three Deep-Primed Cellular Immunotherapy Programs, Including Newly Unveiled Deep TLR, at SITC 2019 Meeting
|
